Cancer Research and Treatment

Jae Hong No

4 Articles

Gynecologic Cancer

Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells: Hye-yon Cho, Yong-Beom Kim, Wook-ha Park, Jae Hong No; Cancer Res Treat. 2021;53(3):819-828. Published online December 16, 2020; DOI: https://doi.org/10.4143/crt.2020.1013

Purpose
This study aimed to evaluate anticancer effects of combination treatment with poly(ADP-ribose) polymerase (PARP) and checkpoint kinase 1 (Chk1) inhibitors in BRCA wild-type ovarian cancer. PARP inhibitors can function as DNA-damaging agents in BRCA wild-type cancer, even if clinical activity is limited. Most epithelial ovarian cancers are characterized by a TP53 mutation causing dysfunction at the G1/S checkpoint, which makes tumor cells highly dependent on Chk1-mediated G/M phase cell-cycle arrest for DNA repair.
Materials and Methods
We investigated the anticancer effects of combination treatment with prexasertib (LY2606368), a selective ATP competitive small molecule inhibitor of Chk1 and Chk2, and rucaparib, a PARP inhibitor, in BRCA wild-type ovarian cancer cell lines (OVCAR3 and SKOV3).
Results
We found that combined treatment significantly decreased cell viability in all cell lines and induced greater DNA damage and apoptosis than in the control and/or using monotherapies. Moreover, we found that prexasertib significantly inhibited homologous recombination–mediated DNA repair and thus showed a marked anticancer effect in combination treatment with rucaparib. The anticancer mechanism of prexasertib and rucaparib was considered to be caused by an impaired G2/M checkpoint due to prexasertib treatment, which forced mitotic catastrophe in the presence of rucaparib.
Conclusion
Our results suggest a novel effective therapeutic strategy for BRCA wild-type epithelial ovarian cancer using a combination of Chk1 and PARP inhibitors.

Citations

Citations to this article as recorded by

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors
Hannah L. Smith, Elaine Willmore, Lisa Prendergast, Nicola J. Curtin
British Journal of Cancer.2024; 131(5): 905. CrossRef
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang
Frontiers in Oncology.2024;[Epub] CrossRef
Update on Combination Strategies of PARP Inhibitors
Zhuoqun Lin, Lingfang Wang, Ziyu Xing, Fenfen Wang, Xiaodong Cheng
Cancer Control.2024;[Epub] CrossRef
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review
Zuzanna Chilimoniuk, Agata Rocka, Martyna Stefaniak, Żaklina Tomczyk, Faustyna Jasielska, Dominika Madras, Agata Filip
Future Oncology.2022; 18(13): 1627. CrossRef
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
Panagiotis A. Konstantinopoulos, Jung-min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Gynecologic Oncology.2022; 167(2): 213. CrossRef
Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages
Cassandra L. R. van Doorn, Sanne A. M. Steenbergen, Kimberley V. Walburg, Tom H. M. Ottenhoff
Frontiers in Immunology.2021;[Epub] CrossRef

7,255 View
238 Download
8 Web of Science
6 Crossref

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors: Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim; Cancer Res Treat. 2017;49(4):1153-1163. Published online February 27, 2017; DOI: https://doi.org/10.4143/crt.2016.463

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.

Citations

Citations to this article as recorded by

Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study
Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song
Breast Cancer Research and Treatment.2024; 206(3): 543. CrossRef
Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin
Current Oncology.2023; 30(2): 1794. CrossRef
Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study
Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk
Annals of Medicine & Surgery.2022;[Epub] CrossRef
Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis
Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias
Medicina.2021; 57(4): 385. CrossRef
Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control
Brändli SP, Palm J, Kowalewski MP, Reichler IM
Theriogenology.2021; 173: 73. CrossRef
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney
Cancer Management and Research.2021; Volume 13: 6537. CrossRef
Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results
Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid
Indian Journal of Surgical Oncology.2019; 10(3): 542. CrossRef
Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, Sara Hurvitz
Clinical Cancer Research.2018; 24(21): 5206. CrossRef

12,452 View
363 Download
10 Web of Science
8 Crossref

Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer: Jeanny Kwon, Keun-Yong Eom, In Ah Kim, Jae-Sung Kim, Young-Beom Kim, Jae Hong No, Kidong Kim; Cancer Res Treat. 2016;48(2):632-640. Published online July 14, 2015; DOI: https://doi.org/10.4143/crt.2015.085

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to compare the prognostic efficacy of the number and location of positive lymph nodes (LN), LN ratio (LNR), and log odds of positive LNs (LODDs) in highrisk cervical cancer treated with radical surgery and adjuvant treatment. Materials and Methods Fifty high-risk patients who underwent radical hysterectomy and pelvic node dissection followed by adjuvant treatment were analyzed retrospectively. The patients had International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IIB. Upper LN is defined as common iliac or higher LN, and LNR is the ratio of positive LNs to harvested LNs. LODDs is log odds between positive LNs and negative LNs. Radiotherapy was delivered to the whole pelvis with median 50.4 Gy/28 Fx± to the para-aortic regions. Platinum-based chemotherapy was used in most patients (93%). The median follow-up duration was 80 months. Results The 5-year disease-free survival (DFS) rate was 76.1%, and the overall survival (OS) rate was 86.4%. Treatment failure occurred in 11 patients, and distant failure (DF) was the dominant pattern (90.9%). In univariate analysis, significantly lower DFSwas observed in patients with perineural invasion, ≥ 2 LN metastases, LNR ≥ 10%, upper LN metastasis, and ≥ –1.05 LODDs. In multivariate analysis, ≥ –1.05 LODDs was the only significant factor for DFS (p=0.011). Of patients with LODDs ≥ –1.05, 40.9% experienced DF. LODDs was the only significant prognostic factor for OS as well (p=0.006). Conclusion LODDs ≥ –1.05 was the only significant prognostic factor for both DFS and OS. In patients with LODDs ≥ –1.05, intensified chemotherapy might be required, considering the high rate of DF.

Citations

Citations to this article as recorded by

Perineural invasion in cervical cancer: A multicenter retrospective study
Xiaolin Chen, Hui Duan, Hongwei Zhao, Fangjie He, Lu Yin, Yueping Liu, Lixia Wang, Chunlin Chen
European Journal of Surgical Oncology.2024; 50(6): 108313. CrossRef
Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors
Angela Santoro, Frediano Inzani, Giuseppe Angelico, Damiano Arciuolo, Emma Bragantini, Antonio Travaglino, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Stefania Sfregola, Alessia Piermattei, Federica Cianfrini, Paola Roberti, Gian Franco Za
Cancers.2023; 15(4): 1137. CrossRef
Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis
Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu
Frontiers in Oncology.2022;[Epub] CrossRef
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database
Christopher G. Smith, Quan Chen, Bin Huang, Rachel W. Miller, Christopher P. DeSimone, Charles S. Dietrich, Frederick R. Ueland, Holly H. Gallion, Edward J. Pavlik, John R. van Nagell, Lauren A. Baldwin Branch
Journal of Gynecologic Surgery.2022; 38(4): 278. CrossRef
The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival
Antoni Llueca, Javier Escrig, Antonio Gil-Moreno, Virginia Benito, Alicia Hernández, Berta Díaz-Feijoo
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy
Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Yonsei Medical Journal.2021; 62(3): 231. CrossRef
The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases—a literature review
Ester P. Olthof, Maaike A. van der Aa, Judit A. Adam, Lukas J. A. Stalpers, Hans H. B. Wenzel, Jacobus van der Velden, Constantijne H. Mom
International Journal of Clinical Oncology.2021; 26(9): 1600. CrossRef
Prognostic implications of ENE and LODDS in relation to lymph node-positive colorectal cancer location
Tengfei Li, Yan Yang, Weidong Wu, Zhongmao Fu, Feichi Cheng, Jiahui Qiu, Qi Li, Kundong Zhang, Zai Luo, Zhengjun Qiu, Chen Huang
Translational Oncology.2021; 14(11): 101190. CrossRef
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy
Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan
Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Radiomic signature as a predictive factor for lymph node metastasis in early‐stage cervical cancer
Yangyang Kan, Di Dong, Yuchen Zhang, Wenyan Jiang, Nannan Zhao, Lu Han, Mengjie Fang, Yali Zang, Chaoen Hu, Jie Tian, Chunming Li, Yahong Luo
Journal of Magnetic Resonance Imaging.2019; 49(1): 304. CrossRef
The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04)
Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha
Cancer Research and Treatment.2018; 50(3): 964. CrossRef
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer
Weiye Deng, Ting Xu, Yifan Wang, Yujin Xu, Pei Yang, Daniel Gomez, Zhongxing Liao
Lung Cancer.2018; 122: 60. CrossRef
Prognostic significance of lymph node ratio in node-positive cervical cancer patients
Ji Hyeon Joo, Young Seok Kim, Joo-Hyun Nam
Medicine.2018; 97(30): e11711. CrossRef
Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer
Jeong Won Lee, Seob Jeon, Seong Taek Mun, Sang Mi Lee
International Journal of Gynecologic Cancer.2017; 27(4): 776. CrossRef

11,849 View
90 Download
22 Web of Science
15 Crossref

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study: Hee Seung Kim, Hwa-Young Choi, Maria Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hyun Hoon Chung, Yong Beom Kim, Yong Sang Song; Cancer Res Treat. 2016;48(1):250-258. Published online March 6, 2015; DOI: https://doi.org/10.4143/crt.2014.324

Abstract PDF PubReader ePub

Purpose
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).
Materials and Methods
The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.
Results
Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted noncomplete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.
Conclusion
CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.

Citations

Citations to this article as recorded by

Correlation between pre-operative platelets count and serum cancer antigen-125 level in epithelial ovarian carcer
Justina Omoikhefe Alegbeleye, Celestine Osita John
Indian Journal of Obstetrics and Gynecology Research.2024; 11(1): 17. CrossRef
Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015
Bing-Qian Tian, Shu-Wen Wang, Jing-Ying Xu, San-Gang Wu, Juan Zhou
Frontiers in Oncology.2024;[Epub] CrossRef
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line
Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar
Clinical and Translational Oncology.2024; 26(12): 3211. CrossRef
The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: A systematic review and meta-analysis
Zihan Zhang, Jinghe Lang
Journal of Medical Biochemistry.2024; 43(4): 323. CrossRef
Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors
Ke Huang, Shengjie Xu, Jiatong Wang, Lili Ge, Juan Xu, Xuemei Jia
Journal of Ovarian Research.2023;[Epub] CrossRef
Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR
Chuan-long Zhang, Xiao-chen Jiang, Yi Li, Xue Pan, Meng-qi Gao, Yan Chen, Bo Pang
Journal of Ovarian Research.2023;[Epub] CrossRef
Trends in Systemic Inflammatory Reaction (SIR) during Paclitaxel and Carboplatin Chemotherapy in Women Suffering from Epithelial Ovarian Cancer
Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kałamacki, Dorota Kiprian, Tomasz Banas
Cancers.2023; 15(14): 3607. CrossRef
Research Progress of the Relationship between Peripheral Blood Indexes and the Diagnosis, Treatment and Prognosis of Ovarian Cancer
洁严
Advances in Clinical Medicine.2023; 13(11): 17362. CrossRef
Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis
Fatemeh Tabatabaei, Hossein Tahernia, Arshin Ghaedi, Aida Bazrgar, Shokoufeh Khanzadeh
BMC Women's Health.2023;[Epub] CrossRef
Comparison of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio levels in ovarian cyst among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan, Indonesia
Mega Sari Dewi, Roy Yustin Simanjuntak, Letta Sari Lintang, Muhammad Fahdhy, Deri Edianto, Makmur Sitepu
Majalah Obstetri & Ginekologi.2023; 31(3): 117. CrossRef
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li
Frontiers in Oncology.2022;[Epub] CrossRef
Evaluation of CA-125 Biomarker in Acute Appendicitis Patients: Correlation with Clinical Symptoms and Lab Results
Mojtaba Ahmadinejad, Seyed A. Hashemi, Alireza Shirzadi, Ali Soltanian, Jafar Ashrafi, Kourosh Kabir, Mahla Alizadeh
The Open Public Health Journal.2021; 14(1): 162. CrossRef
The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain
Na Wang, Cuiping Li, Yujie Yang, Yu Guan, Fengjiao Wang, Yan Wang, Wei Zhao
World Neurosurgery.2021; 149: 502. CrossRef
Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art
Michal Mleko, Kazimierz Pitynski, Elzbieta Pluta, Aleksandra Czerw, Katarzyna Sygit, Beata Karakiewicz, Tomasz Banas
Cancer Management and Research.2021; Volume 13: 5491. CrossRef
The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis
Ting Chen, Jia‐Ling Wei, Ting Leng, Fei Gao, Shun‐yu Hou
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii
International Journal of Molecular Sciences.2021; 22(24): 13650. CrossRef
Prognostic significance of preoperative circulating FAR and FCI scores in patients with ovarian cancer
Huige Wang, Yanjun Shen, Xiaoyan Ding, Yongfen Ding, Ling Cheng, Juan Lai
Clinica Chimica Acta.2020; 509: 252. CrossRef
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications
Wei Chen, Siyuan Zhong, Boer Shan, Shuling Zhou, Xiaohua Wu, Huijuan Yang, Shuang Ye
Journal of Ovarian Research.2020;[Epub] CrossRef
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer
Julie My Van Nguyen, Sarah Elizabeth Ferguson, Marcus Q Bernardini, Taymaa May, Stephane Laframboise, Liat Hogen, Geneviève Bouchard-Fortier
International Journal of Gynecologic Cancer.2020; 30(9): 1378. CrossRef
Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management
Aeran Seol, Se Ik Kim, Yong Sang Song
Sports Medicine and Health Science.2020; 2(4): 202. CrossRef
Associations between Blood Cell Profiles and Primary Open-Angle Glaucoma: A Retrospective Case-Control Study
Binghua Tang, Shengjie Li, Jianping Han, Wenjun Cao, Xinghuai Sun
Ophthalmic Research.2020; 63(4): 413. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma
Kosuke Yoshida, Nobuhisa Yoshikawa, Akira Shirakawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
Jie-Ping Chen, Qi-Dan Huang, Ting Wan, Hua Tu, Hai-Feng Gu, Jun-Ya Cao, Ji-Hong Liu
Journal of Ovarian Research.2019;[Epub] CrossRef
Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer
Jin Wang, Jinglei Qu, Zhi Li, Xiaofang Che, Jing Liu, Yuee Teng, Bo Jin, Mingfang Zhao, Yunpeng Liu, Xiujuan Qu
Journal of Clinical Laboratory Analysis.2018;[Epub] CrossRef
Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review
Naoko Komura, Seiji Mabuchi, Eriko Yokoi, Katsumi Kozasa, Hiromasa Kuroda, Tomoyuki Sasano, Yuri Matsumoto, Tadashi Kimura
International Journal of Clinical Oncology.2018; 23(1): 104. CrossRef
Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies
Zhe Zhao, Xinrui Zhao, Jingjing Lu, Jing Xue, Peishu Liu, Hongluan Mao
Archives of Gynecology and Obstetrics.2018; 297(4): 849. CrossRef
The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis
Joanna L. Sylman, Annachiara Mitrugno, Michelle Atallah, Garth W. Tormoen, Joseph J. Shatzel, Samuel Tassi Yunga, Todd H. Wagner, John T. Leppert, Parag Mallick, Owen J. T. McCarty
Frontiers in Oncology.2018;[Epub] CrossRef
Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer
Katarzyna Bednarska, Ewa Król, Ewa Głowacka, Hanna Romanowicz, Krzysztof Szyłło, Magdalena Klink, Zofia Sułowska, Marek Nowak
Medicine.2018; 97(12): e0180. CrossRef
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, Valentina Gallà, Filippo Greco, Claudia Casanova, Lucia Longo, Gennaro Cormio, Michele Orditura, Alessandra Bologna, Laura Zavallone, Jole Ventriglia, Elisena Franzese, Vera Loizzi, Donatella Giardina, Ev
Targeted Oncology.2018; 13(4): 469. CrossRef
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma
Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju
International Journal of Gynecological Cancer.2018; 28(6): 1108. CrossRef
Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis
Gaowen Chen, Lin Zhu, Yulu Yang, Yusheng Long, Xiangyuan Li, Yifeng Wang
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer
E Sun Paik, Minhee Shim, Hyun Jin Choi, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae
Cancer Biomarkers.2017; 17(4): 419. CrossRef
Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis
Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux
Gynecologic Oncology.2017; 145(3): 584. CrossRef
The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer
Anastasia Prodromidou, Panagiotis Andreakos, Charalampos Kazakos, Dimitrios Eftimios Vlachos, Despina Perrea, Vasilios Pergialiotis
Inflammation Research.2017; 66(6): 467. CrossRef
The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma
Lihong Cong, Likuan Hu
International Immunopharmacology.2017; 46: 75. CrossRef
Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis
Yanlin Luo, Hee Seung Kim, Miseon Kim, Maria Lee, Yong Sang Song
Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway
Boyun Kim, Hee Seung Kim, Soochi Kim, Guy Haegeman, Benjamin K. Tsang, Danny N. Dhanasekaran, Yong Sang Song
Cancer Research and Treatment.2017; 49(2): 338. CrossRef
Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma
Hongwei Zhang, Jiaqi Lu, Yingying Lu, Jiayi Zhou, Zehua Wang, Haiou Liu, Congjian Xu, Renato Franco
PLOS ONE.2017; 12(5): e0177520. CrossRef
Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis
Shubo Chen, Liu Zhang, Guangyue Yan, Sijin Cheng, Abdel Hamid Fathy, Nana Yan, Yongzhao Zhao
BioMed Research International.2017; 2017: 1. CrossRef
Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients
Quan Zhou, Li Hong, Man-Zhen Zuo, Ze He
Oncotarget.2017; 8(40): 68938. CrossRef
Predictive value of systematic inflammatory response biomarkers (NLR, LMR, PLR) in patients with ovarian cancer.
Urszula Rychlik, Ewa Wójcik, Jadwiga Tarapacz, Katarzyna Brandys, Zofia Stasik, Beata Kala, Jan K. Kulpa, Wiktor Szatkowski, Paweł Blecharz, Jerzy Jakubowicz
Diagnostyka Laboratoryjna.2017; 53(3): 139. CrossRef
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy
Yi Miao, Qin Yan, Shuangdi Li, Bilan Li, Youji Feng
Cancer Biomarkers.2016; 17(1): 33. CrossRef
Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma
Jia-Zhu Wu, Tian Tian, Ying Huang, Jin-Hua Liang, Yi Miao, Li Wang, Ji Xu, Xiao-Yan Qu, Lei Fan, Jian-Yong Li, Wei Xu
Cancer Biomarkers.2016; 17(2): 205. CrossRef
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
Huimin Bai, Guisha Sha, Meizhu Xiao, Huiqiao Gao, Dongyan Cao, Jiaxin Yang, Jie Chen, Yue Wang, Zhenyu Zhang, Keng Shen
Oncotarget.2016; 7(13): 15566. CrossRef
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer
Ghazala Khan, Suzanne E. Brooks, Ken I. Mills, Barbara-Ann Guinn
Biomarkers in Cancer.2015; 7: BIC.S28378. CrossRef

17,072 View
166 Download
50 Web of Science
45 Crossref

Author index